Theranos: the $9 billion blood-testing company built on technology that didn't work
Theranos claimed its compact machines could run a wide range of blood tests on a few drops of blood. They couldn't; the company ran many tests on modified commercial equipment, and results were unreliable. Investigative reporting exposed it, regulators acted, and its leaders were convicted of fraud.
- Primary cause: Fraud & misreported numbers
- Technology didn't deliver
- Governance failure
- Founded
- 2003
- Ended
- 2018
- Headquarters
- United States
- Sector
- Health
- Capital raised
- ~$700M+
- Peak valuation
- ~$9B (2014)
What happened
Dissolved in September 2018. Founder Elizabeth Holmes was convicted of defrauding investors in 2022 and sentenced to more than 11 years in prison; former president Ramesh 'Sunny' Balwani was also convicted.
What Theranos was
Elizabeth Holmes founded Theranos in 2003 after leaving Stanford. By 2014 the company was valued at about $9 billion, had a retail partnership with Walgreens, and a board that included former cabinet secretaries and senior military leaders.
In October 2015, The Wall Street Journal's John Carreyrou reported that Theranos's own devices ran only a small number of tests and had accuracy problems. Regulators found serious deficiencies in its lab, and Theranos voided two years of results from its devices. The SEC charged the company and its leaders in 2018, it dissolved later that year, and Holmes was convicted in 2022.
Why it failed
- 1
The core technology didn't do what was promised
Running many accurate tests on a tiny blood sample is a genuinely hard scientific problem. Instead of acknowledging the limits, the company presented its device as ready and quietly used commercially available analyzers for many tests.
- 2
Secrecy replaced validation
Theranos avoided peer review and independent validation, citing trade secrets. In healthcare, where results drive medical decisions, outside scrutiny is a safety mechanism; without it, problems reached patients.
- 3
A board without the expertise to ask hard questions
The board was full of prominent names but lacked deep expertise in laboratory medicine. Investors leaned on reputation and partnerships rather than technical diligence.
The product lesson
In regulated, high-stakes domains, 'fake it till you make it' isn't a growth tactic — it is fraud, and people get hurt. Product leaders should insist on independent validation of any claim that affects users' safety or money, and treat a culture of secrecy and retaliation against internal critics as a red flag in its own right.
Early warning sign to watch for
Employees who raise concerns about results are sidelined, and the core claims can't be checked by anyone outside the company.
Compiled from public reporting, court records, and company statements. Figures are approximate. Where legal proceedings are mentioned, convictions are described as convictions and charges as allegations. Corrections welcome at hello@productmanagement.space.